Anika Therapeutics (NSDQ:ANIK) has inked a deal to extend its two-year-long collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst. The group plans to focus its efforts on developing a novel therapeutic candidate to treat rheumatoid arthritis. Anika and UMass reported that it hopes to bring the product into clinical trials […]
Pharmaceuticals
Adherium to expand in U.S. market with direct-to-consumer push for smart inhaler tech
Adherium Ltd. (ASK:ADR), which sells a smart inhaler technology in Europe and Australia, is reportedly looking to jump into the direct-to-consumer U.S. market in the first half of this year. The New Zealand-based company has a deal with AstraZeneca (NYSE:AZN) to combine its Smartinhaler monitoring device with the Symbicort inhaler, but CEO Arik Anderson told MobiHealthNews that he is […]
Ocular Therapeutix plans $32.5m public offering to fund NDA resubmission for Dextenza
Updated to include the offering’s pricing information. Ocular Therapeutix (NSDQ:OCUL) said today that it plans to launch an underwritten public offering of 6.5 million shares of common stock at $5.00 apiece to help fund the resubmission of its new drug application for Dextenza, an ocular post-surgical pain-relief implant that was rejected by the FDA last year. The […]
How conversations with virtual people could help mitigate the opioid crisis
It often starts in the doctor’s office or the emergency room. A patient has broken their leg and will be in pain for weeks. Another patient has had back surgery and is on their way home, but it will take time before they’re fully recovered. A third patient has returned for a consult about the […]
Reva implants first Fantom bioresorbable scaffold in Italy
Reva Medical (ASX:RVA) said yesterday that the first Fantom bioresorbable scaffold was implanted in Italy. The sirolimus-eluting device is made using a tyrosine-derived polymer that is visible under x-ray. Data from Reva’s Fantom II clinical trial found that the device resulted in a 4.2% rate of major adverse cardiac events after 12 months and 5.6% after […]
Researchers develop capsule to deliver a week’s worth of HIV drugs
A team of researchers from the Massachusetts Institute of Technology and Brigham & Women’s Hospital have developed a drug-delivery capsule that can deliver a week’s worth of HIV drugs in a single dose. The technology is designed to make it easier for people with HIV to deal with the strict schedule of medications they need […]
FDA, FTC warn companies over deceptive opioid cessation products
The FDA and the Federal Trade Commission have posted joint warning letters to companies that make and distribute opioid cessation products. The two watchdogs warned that the companies are illegally marketing their unapproved products as treatments or even cures for people with opioid addiction and withdrawal. Selling unapproved products as therapies for opioid addiction is […]
Pharma revenue drives Johnson & Johnson’s Q4 beat
Shares in Johnson & Johnson (NYSE:JNJ) fell yesterday after the healthcare giant topped Wall Street’s expectations for fourth-quarter results but missed analysts’ forecast for the full-year. Despite taking a $13.6 billion hit to its unremitted foreign earnings thanks to new efforts to reform the U.S. tax system, the company said it is pleased with the legislation […]
CDC group tackles access to birth control for women in Puerto Rico
Between May 2016 and August last year, a group organized by the CDC provided services to more than 21,000 women in Puerto Rico in an attempt to boost access to contraception, lower the rate of unintended pregnancy and lessen the number of Zika-related birth defects on the island. Last week, The Lancet Public Health examined the […]
Aerie Pharmaceuticals prices $75m public offering
Aerie Pharmaceuticals (NSDQ:AERI) has priced an underwritten public offering of $75 million in shares of its common stock. The Irvine, Calif.-based company also plans to grant underwriters a 30-day option to buy up to $11.3 million in shares of common stock. Aerie reported that it plans to use the net proceeds from the offering to fund […]